Nov 20, 2018
TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
Nov 13, 2018
Phase 2 Data for Galmed Pharmaceutical's Aramchol(TM) in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018
Nov 12, 2018
NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)
Nov 09, 2018
Predicting Clinical Outcomes With Multiparametric MRI Featuring Liver cT1 Equal to Biopsy, According to Research Presented at The Liver Meeting® 2018
Nov 09, 2018
NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH
Nov 06, 2018
NGM Bio Announces Multiple Presentations at AASLD's The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313
Nov 05, 2018
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
Oct 25, 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Oct 24, 2018
TaiwanJ Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Study of JKB-122 on Non-Alcoholic Fatty Liver Disease (NAFLD)
Oct 08, 2018
Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA)
Oct 04, 2018
Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018
Oct 01, 2018
Liver Cancer is on the Rise Despite Increasing Number of Treatments
Sep 18, 2018
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Sep 13, 2018
Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease
Sep 05, 2018
Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH)
Aug 30, 2018
The Kinetix Group Partners with Rimidi to Launch a Clinical Care Partnership for the Management of Nonalcoholic Steatohepatitis (NASH)
Aug 23, 2018
The Nonalcoholic Steatohepatitis (NASH) Network in Collaboration with Echosens Launches a Real World Evidence Model
Aug 10, 2018
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
Jul 31, 2018
Large Population Imaging Study Reveals Utility of LiverMultiScan's Corrected T1 Measure as Potential Biomarker for Liver Health in Metabolic Diseases
Jul 05, 2018
HistoIndex Welcomes Its New CEO on Board